Nuo Therapeutics, Inc. (AURX): who owns it and who trades it
As of Oct 30, 2026, AURX insiders reported 1 open-market sale worth $300K and 2 purchases worth $9.5K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was David Emerson Jorden (CEO), with $300K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, AURX insiders reported $9.5K of open-market purchases and $300K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | David Emerson Jorden | CEO | Purchase | 7,984 | $1.09 | $8.7K | Form 4 |
| Aug 27, 2026 | David Emerson Jorden | CEO | Purchase | 789 | $1.07 | $844 | Form 4 |
| Nov 28, 2025 | David Emerson Jorden | CEO | Sale | 200,000 | $1.50 | $300K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David Emerson Jorden | CEO/CFO, Director | $9.5K | $300K | Aug 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AURX short interest
Low short interest. Less than 0.1% of AURX shares are sold short. Over the last 12 reports the number of shares short went up 832%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4,326 AURX shares were sold short, 0.0% of the shares outstanding, up 4872.4% from the report before. At the average daily volume of 20,537 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4,326 | 0.01% | +4872% | 20,537 | 1.0 |
| Oct 15, 2026 | 87 | 0.00% | -84% | 2,023 | 1.0 |
| Sep 30, 2026 | 551 | 0.00% | -89% | 4,968 | 1.0 |
| Sep 15, 2026 | 5,153 | 0.01% | +62% | 8,199 | 1.0 |
| Aug 31, 2026 | 3,185 | 0.01% | +204% | 11,041 | 1.0 |
| Aug 14, 2026 | 1,046 | 0.00% | -32% | 1,199 | 1.0 |
| Jul 31, 2026 | 1,546 | 0.00% | +1961% | 6,921 | 1.0 |
| Jul 15, 2026 | 75 | 0.00% | No change | 733 | 1.0 |
| Jun 30, 2026 | 75 | 0.00% | -96% | 3,124 | 1.0 |
| Jun 15, 2026 | 2,090 | 0.00% | +145% | 5,768 | 1.0 |
| May 29, 2026 | 854 | 0.00% | +84% | 3,307 | 1.0 |
| May 15, 2026 | 464 | 0.00% | -54% | 14,767 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Nuo Therapeutics company events
Nuo Therapeutics filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 6, 2026.
- Oct 6, 2026AgreementNuo Therapeutics, Inc. entered into a Consent and Extension to the Amended and Restated Loan and Security Agreement dated May 29, 2026 with the lenders (each, a “Lender” and, collectively, the “Lenders”) to the Loan Agreement solely to extend the closing date of the funding commitment of $325,000… Filing
- Aug 17, 2026ResultsReleased financial results. Filing
- Jun 3, 2026AgreementNuo Therapeutics, Inc. entered into an Amended and Restated Loan and Security Agreement with five lenders. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Jan 26, 2026AgreementNuo Therapeutics, Inc. entered into a Loan and Security Agreement with four lenders. Filing
- Dec 17, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Nuo Therapeutics financials
Questions about Nuo Therapeutics, Inc. (AURX) stock
Are AURX insiders buying or selling?
In the last 12 months, AURX insiders reported 2 open-market purchases worth $9.5K and 1 sale worth $300K. The latest trade was on Aug 28, 2026. See every trade.
What is the short interest in AURX?
As of Oct 30, 2026, 4,326 AURX shares were sold short, 0.0% of the shares outstanding, up 4872.4% from the report before. At the average daily volume of 20,537 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.